Basch E., Loblaw D.A., Oliver T.K., Carducci M., Chen R.C., Frame J.N., Garrels K., Hotte S., Kattan M.W., Raghavan D., Saad F., Taplin M.-E., Walker-Dilks C., Williams J., Winquist E., Bennett C.L., Wootton T., Rumble R.B., Dusetzina S.B., Virgo K.S.
Journal of Clinical Oncology 2014 32:30 (3436-3448)
Purpose To provide treatment recommendations for men with metastatic castration-resistant prostate cancer (CRPC). Methods The American Society of Clinical Oncology and Cancer Care Ontario convened an expert panel to develop evidence-based recommendations informed by a systematic review of the literature. Results When added to androgen deprivation, therapies demonstrating improved survival, improved quality of life (QOL), and favorable benefit-harm balance include abiraterone acetate/prednisone, enzalutamide, and radium-223 (223Ra; for men with predominantly bone metastases). Improved survival and QOL with moderate toxicity risk are associated with docetaxel/prednisone…(ver más)